H-D-Val-Phe-Lys-OH | 99296-76-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: H-D-Val-Phe-Lys-OH
• 英文别名: (2S)-6-amino-2-[[(2S)-2-[[(2R)-2-amino-3-methylbutanoyl]amino]-3-phenylpropanoyl]amino]hexanoic acid
• CAS: 99296-76-1
• 化学式: C₂₀H₃₂N₄O₄
• 分子量: 392.498
• InChiKey: MHHAWNPHDLCPLF-YESZJQIVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  28
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  148
• 氢给体数：
  5
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  (S)-6-Benzyloxycarbonylamino-2-[(S)-2-((R)-2-benzyloxycarbonylamino-3-methyl-butyrylamino)-3-phenyl-propionylamino]-hexanoic acid 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 、 水 为溶剂， 生成 H-D-Val-Phe-Lys-OH
  参考文献：
  名称：

  Markowska, Agnieszka; Midura-Nowaczek, Krystyna; Bruzgo, Irena, Acta poloniae pharmaceutica, 2007, vol. 64, # 4, p. 355 - 358

  摘要：

  DOI：

文献信息

• Water-Soluble CC-1065 Analogs and Their Conjugates
  申请人：Beusker Patrick Henry

  公开号：US20090318668A1

  公开（公告）日：2009-12-24

  This invention relates to novel analogs of the DNA-binding alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and their conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.

  这项发明涉及DNA结合烷基化剂CC-1065的新型类似物及其结合物。此外，该发明涉及用于制备上述剂和它们的结合物的中间体。这些结合物设计为在一个或多个激活步骤之后以及/或由结合物控制的速率和时间跨度下释放它们的（多种）荷载，以便选择性地传递和/或可控地释放一个或多个所述的DNA烷基化剂。这些剂、结合物和中间体可用于治疗以不良（细胞）增殖为特征的疾病。例如，这项发明的剂和结合物可用于治疗肿瘤。
• Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation
  申请人：Beusker Patrick Henry

  公开号：US20080311136A1

  公开（公告）日：2008-12-18

  This invention relates to compounds comprising one or more therapeutic and/or diagnostic moieties and one or more functional moieties linked together via one or more triazole-containing linkers and to their intermediates and methods of their preparation. The triazole-containing linker may optionally contain one or more conditionally-cleavable or conditionally-transformable moieties and one or more spacer systems in between said moiety/moieties and the one or more therapeutic and/or diagnostic moieties.

  本发明涉及一种化合物，其中包含一个或多个治疗和/或诊断基团，以及一个或多个功能基团，通过一个或多个三唑含链连接在一起，以及它们的中间体和制备方法。三唑含链连接物可以选择性地包含一个或多个有条件可裂解或有条件可转化的基团，以及一个或多个间隔系统，位于所述基团和一个或多个治疗和/或诊断基团之间。
• [EN] SUBSTITUTED CC-1065 ANALOGS AND THEIR CONJUGATES<br/>[FR] ANALOGUES CC-1065 SUBSTITUÉS ET LEURS CONJUGUÉS
  申请人：SYNTARGA BV

  公开号：WO2009017394A1

  公开（公告）日：2009-02-05

  This invention relates to novel agents that are analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and their conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.

  本发明涉及一种与DNA-烷基化剂CC-1065类似的新型剂，以及它们的共轭物。此外，本发明涉及用于制备所述剂和它们的共轭物的中间体。共轭物被设计为在一个或多个激活步骤后释放它们的（多个）有效载荷和/或由共轭物控制的速率和时间跨度，以有选择地传递和/或可控释放一个或多个所述的DNA烷基化剂。这些剂、共轭物和中间体可用于治疗其特征为不受欢迎的（细胞）增殖的疾病。例如，本发明的剂和共轭物可用于治疗肿瘤。
• Elongated and multiple spacers in activatible produgs
  申请人：——

  公开号：US20040121940A1

  公开（公告）日：2004-06-24

  This invention is directed to prodrugs that can be activated at the preferred site of action in order to selectively deliver the corresponding therapeutic parent drugs to target cells or to the target site. This invention will therefore primarily but not exclusively relate to tumor cells as target cells. More specifically the prodrugs are compounds of the formula V—(W)k-(X)l-A-Z, wherein: V is a specifier; (W)k-(X)l-A is an elongated self-elimination spacer system; W and X are each a l,(4+2n) electronic cascade spacer, being the same or different; A is either a spacer group of formula (Y) m wherein: Y is a l,(4+2n) electronic cascade spacer, or a group of formula U being a cyclisation elimination spacer; Z is a therapeutic drug; k, l and m are integers from 0 (included) to 5 (included); n is an integer of 0 (included) to 10 (included), with the provisos that:—when A is (Y)m: k+l+m 1, and if k+l+m=1;—when A is U: k+l 1.

  本发明涉及一种前药，可以在优选的作用部位被激活，以有选择地将相应的治疗原药物递送到靶细胞或靶部位。因此，本发明主要但不仅限于与肿瘤细胞作为靶细胞相关。更具体地说，前药是公式V—(W)k-(X)l-A-Z的化合物，其中：V是说明符；(W)k-(X)l-A是一个延长的自我消除间隔系统；W和X分别是l，（4+2n）电子级联间隔器，可以相同也可以不同；A是公式（Y）m的间隔基，其中：Y是l，（4+2n）电子级联间隔器，或者是公式U的基团，是一个环化消除间隔器；Z是治疗药物；k、l和m是从0（包括）到5（包括）的整数；n是0（包括）到10（包括）的整数，但限制条件是：当A是（Y）m时：k+l+m≥1，如果k+l+m=1；当A是U时：k+l≥1。
• PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION
  申请人：Invivogen

  公开号：EP3505188A1

  公开（公告）日：2019-07-03

  The present invention provides a Pro-cyclic dinucleotide (Pro-CDN) comprising a STING agonist cyclic dinucleotide which is coupled to a linker system. The Pro-CDNs of the present invention can be metabolized at a targeted site into CDNs and exert their full immunomodulatory effects at said targeted site. The present invention also provides conjugates wherein a Pro-CDN is conjugated to a Biologically Active Molecule (BAM) such as e.g. a cytotoxic molecule, a lipid, a protein, a peptide, a nucleic acid, a sugar or a PRR ligand. The invention provides also methods related to the use of such compounds to perform their activities at their targeted sites, to exert cytotoxic, cytostatic or immunomodulatory effects, to treat or to prevent diseases such as cancers, immunological disorders or infections.

  本发明提供了一种原环二核苷酸（Pro-CDN），它由 STING 激动剂环二核苷酸与连接体系统耦合而成。本发明的 Pro-CDN 可在靶点代谢成 CDN，并在所述靶点充分发挥免疫调节作用。本发明还提供了共轭物，其中 Pro-CDN 与生物活性分子（BAM）共轭，例如细胞毒性分子、脂质、蛋白质、肽、核酸、糖或 PRR 配体。本发明还提供了与使用此类化合物有关的方法，以在其靶位点发挥活性，产生细胞毒性、细胞抑制或免疫调节作用，治疗或预防癌症、免疫紊乱或感染等疾病。